Home > Insider Trading > Filing (0001628280-25-005698)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501697	X4 Pharmaceuticals Inc	XFOR	Biological Products, (No Disgnostic Substances) (2836)	273181608

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1644137	Mark Baldry	C/O X4 Pharmaceuticals, Inc. 61 North Beacon Street 4Th Floor Boston MA 02134	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-05-17	21,646	$0.68	115,769	No	4	P	Direct
Common Stock	Acquisiton	2024-11-15	13,404	$0.34	129,173	No	4	P	Direct
Common Stock	Acquisiton	2025-02-12	600,000	$0.00	729,173	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	A	Direct

Footnotes

The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported.
Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.